including research on medical uses and the effects of impairment. (D) Lack of access to medical cannabis and research, particularly with respect to Federal agencies. (E) Lack of medical cannabis training at publicly funded medical training centers. (F) Lack of consistent regulations for cannabis product and safety, use, and labeling requirements, including requirements to protect youth and reduce harms to youth. (G) Lack of efficient cannabis revenue reporting and collecting, including efficient and tenable Federal revenue frameworks. (H) Lack of guidance for cannabis crop production, sale, intrastate, interstate, and international trade. (I) Lack of guidance regarding the successful coexistence of individual hemp and cannabis industries, including prevention of cross pollination of cannabis and hemp products. (J) Expected disruptions to established State and local regulatory systems with regard to cannabis as a result of Federal regulation. (K) Any other barriers to Federal cannabis legalization identified by the commission. (2) Public comment